[HTML][HTML] Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised …
RL Goodall, SK Meredith, AJ Nunn, A Bayissa… - The Lancet, 2022 - thelancet.com
Background The STREAM stage 1 trial showed that a 9-month regimen for the treatment of
rifampicin-resistant tuberculosis was non-inferior to the 20-month 2011 WHO-recommended …
rifampicin-resistant tuberculosis was non-inferior to the 20-month 2011 WHO-recommended …
Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: A randomised, double-blind, phase 3 trial
Background Tixagevimab–cilgavimab is a neutralising monoclonal antibody combination
hypothesised to improve outcomes for patients hospitalised with COVID-19. We aimed to …
hypothesised to improve outcomes for patients hospitalised with COVID-19. We aimed to …
Characteristics and outcomes of admitted patients infected with SARS-CoV-2 in Uganda
B Kirenga, W Muttamba, A Kayongo… - BMJ open …, 2020 - bmjopenrespres.bmj.com
Rationale Detailed data on the characteristics and outcomes of patients with COVID-19 in
sub-Saharan Africa are limited. Objective We determined the clinical characteristics and …
sub-Saharan Africa are limited. Objective We determined the clinical characteristics and …
Efficacy of convalescent plasma for treatment of COVID-19 in Uganda
B Kirenga, P Byakika-Kibwika… - BMJ open …, 2021 - bmjopenrespres.bmj.com
Rationale Convalescent plasma (CCP) has been studied as a potential therapy for COVID-
19, but data on its efficacy in Africa are limited. Objective In this trial we set out to determine …
19, but data on its efficacy in Africa are limited. Objective In this trial we set out to determine …
[HTML][HTML] High prevalence of hypertension and cardiovascular disease risk factors among medical students at Makerere University College of Health Sciences …
Background Cardiovascular disease has become a leading global health challenge
representing the largest cause of mortality in adults worldwide. Non communicable diseases …
representing the largest cause of mortality in adults worldwide. Non communicable diseases …
[HTML][HTML] Trends of admissions and case fatality rates among medical in-patients at a tertiary hospital in Uganda; A four-year retrospective study
R Kalyesubula, I Mutyaba, T Rabin, I Andia-Biraro… - PloS one, 2019 - journals.plos.org
Background Sub-Saharan Africa suffers from a dual burden of infectious and non-
communicable diseases. There is limited data on causes and trends of admission and death …
communicable diseases. There is limited data on causes and trends of admission and death …
Music and dance in respiratory disease management in Uganda: a qualitative study of patient and healthcare professional perspectives
KEJ Philip, LL Cartwright, D Westlake, G Nyakoojo… - BMJ open, 2021 - bmjopen.bmj.com
Introduction Music and dance are increasingly used as adjunctive arts-in-health
interventions in high-income settings, with a growing body of research suggesting …
interventions in high-income settings, with a growing body of research suggesting …
Perceptions of epilepsy among first-year medical students at Mulago Hospital in Kampala, Uganda
J Bigelow, S Berrett, I Kimuli, E Katabira - Epilepsy & Behavior, 2015 - Elsevier
Epilepsy is associated with stigma throughout the world, which leads to poor treatment of
people with epilepsy (PWE). In Uganda, there are more than 75,000 PWE and a large …
people with epilepsy (PWE). In Uganda, there are more than 75,000 PWE and a large …
[HTML][HTML] SARS-CoV-2-Associated multisystem inflammatory syndrome in a child in Uganda: a paediatric experience in a resource-limited setting
T Piloya, L Nakiyingi, I Kimuli, J Kayima… - Case Reports in …, 2022 - hindawi.com
SARS-CoV-2-associated Multisystem Inflammatory Syndrome in children (MIS-C) has been
described in developed settings that have reported a high burden of COVID-19 cases …
described in developed settings that have reported a high burden of COVID-19 cases …
[HTML][HTML] Feasibility of collecting and processing of COVID-19 convalescent plasma for treatment of COVID-19 in Uganda
W Muttamba, J Lusiba, LO Namakula… - PloS one, 2021 - journals.plos.org
Introduction Evidence that supports the use of COVID-19 convalescent plasma (CCP) for
treatment of COVID-19 is increasingly emerging. However, very few African countries have …
treatment of COVID-19 is increasingly emerging. However, very few African countries have …